share_log

10-Q/A: Quarterly report (Amendment)

10-Q/A: Quarterly report (Amendment)

10-Q/A:季度報表(修正版)
美股SEC公告 ·  2024/11/21 22:20

Moomoo AI 已提取核心訊息

ENDRA Life Sciences fully repaid its CAD 40,000 loan from Toronto-Dominion Bank during the nine months ended September 30, 2024. The company's authorized capital consisted of 20 million common shares and 10 million preferred shares as of September 30, 2024, with 534,863 common shares outstanding.ENDRA conducted a registered offering on June 4, 2024, issuing 3,490 common shares and pre-funded warrants for 31,666 shares, along with Series A and B warrants for 178,255 shares each. The offering raised net proceeds of $7,338,333. The company also entered a new At-The-Market Issuance Sales Agreement in February 2024 for up to $6.2 million, replacing a previous agreement.On August 20, 2024, ENDRA implemented a 1-for-50 reverse stock split, adjusting all share counts and prices. The company granted stock options with a fair value of $77,418 during the nine months ended September 30, 2024. Additionally, 46 shares of restricted stock valued at $80,000 vested during this period.
ENDRA Life Sciences fully repaid its CAD 40,000 loan from Toronto-Dominion Bank during the nine months ended September 30, 2024. The company's authorized capital consisted of 20 million common shares and 10 million preferred shares as of September 30, 2024, with 534,863 common shares outstanding.ENDRA conducted a registered offering on June 4, 2024, issuing 3,490 common shares and pre-funded warrants for 31,666 shares, along with Series A and B warrants for 178,255 shares each. The offering raised net proceeds of $7,338,333. The company also entered a new At-The-Market Issuance Sales Agreement in February 2024 for up to $6.2 million, replacing a previous agreement.On August 20, 2024, ENDRA implemented a 1-for-50 reverse stock split, adjusting all share counts and prices. The company granted stock options with a fair value of $77,418 during the nine months ended September 30, 2024. Additionally, 46 shares of restricted stock valued at $80,000 vested during this period.
ENDRA Life Sciences在截至2024年9月30日的九個月內,全額償還了來自多倫多道明銀行的40,000加元貸款。截至2024年9月30日,該公司的授權資本包括2000萬普通股和1000萬優先股,已發行的普通股爲534,863股。ENDRA於2024年6月4日進行了註冊發行,發行了3,490股普通股和預融資Warrants 31,666股,以及系列A和B Warrants各178,255股。該次發行籌集了733,833美元的淨收入。公司還在2024年2月簽署了一份新協議,最大額度爲620萬美元,取代了之前的協議。2024年8月20日,ENDRA實施了1比50的反向股票拆分,調整了所有股數和價格。在截至2024年9月30日的九個月內,該公司授予了公允價值爲77,418美元的期權。此外,在此期間,46股限制性股票的價值爲80,000美元,獲得了生效。
ENDRA Life Sciences在截至2024年9月30日的九個月內,全額償還了來自多倫多道明銀行的40,000加元貸款。截至2024年9月30日,該公司的授權資本包括2000萬普通股和1000萬優先股,已發行的普通股爲534,863股。ENDRA於2024年6月4日進行了註冊發行,發行了3,490股普通股和預融資Warrants 31,666股,以及系列A和B Warrants各178,255股。該次發行籌集了733,833美元的淨收入。公司還在2024年2月簽署了一份新協議,最大額度爲620萬美元,取代了之前的協議。2024年8月20日,ENDRA實施了1比50的反向股票拆分,調整了所有股數和價格。在截至2024年9月30日的九個月內,該公司授予了公允價值爲77,418美元的期權。此外,在此期間,46股限制性股票的價值爲80,000美元,獲得了生效。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息